Medical Monitoring Director

Let’s build the future of medicine - together.

Remote | Full-time | $260,000 - $320,000

YOUR ROLE

As a Medical Monitoring Director at Enveda, you'll be a sponsor physician on our clinical trials: medical monitor on the studies you take on, the physician who oversees the consultant medical monitors on the rest, and, as trials move in house, the person who builds the in-house medical monitoring team. You'll report to the SVP, Clinical Development, work day to day with the clinical leads, Clinical Operations, Biostatistics, and our in-house Pharmacovigilance team, and be the clinical owner of the AI tools our engineers build for blinded safety monitoring. The medical decisions on your studies are yours, and the consultant monitors work to plans you sign. This is a high impact opportunity where you'll influence the medical oversight of a three-program clinical pipeline while collaborating with some of the brightest minds in the industry.

 
WHAT YOU'LL DO

Serve as the sponsor's medical monitor on your studies, blinded where the study is blinded: eligibility and protocol questions from sites, the sponsor's causality assessment on every serious adverse event, and the medical judgment calls the protocol asks of the sponsor's physician

Sit on the dose-escalation safety review committees for our Phase 1 studies and chair the internal blinded safety review for each study, presenting the sponsor's update in the open session of the independent data monitoring committee where a study has one

Write the medical monitoring plans, own the protocol's stopping rules, dose-modification rules, and safety monitoring schedule with each clinical lead, and contribute the medical content of investigator's brochures, safety update reports, and study reports

Do the medical review the data needs: protocol deviations, MedDRA and WHODrug coding, SAE reconciliation, and the listings before database lock

Set the standard for the consultant medical monitors: onboard them, define the plans and escalation paths they work to, review their decisions, and share the 24-hour medical monitor line with them

Be the clinical owner of the AI tools Enveda's engineers build for blinded safety monitoring: define what a medical monitor needs to see, set the flag rules, write the acceptance criteria, and sign off on each release. The tools work on blinded data only and flag and draft for you. Seriousness and causality are assessed by you, expectedness and reportability by Pharmacovigilance, which also holds the unblinding, and none of them by a tool

Train investigators and sites on safety reporting and eligibility, and keep the function inspection-ready with SOPs and a searchable record of medical decisions

Build the in-house medical monitoring team as trials move in house: define the roles, then hire and lead as the team is approved

WHAT WE'RE LOOKING FOR

MD or DO (or equivalent) who has completed residency training and practiced clinically. Board certification and an active medical license are preferred

5 or more years in industry medical monitoring or drug safety, including hands-on medical monitoring of Phase 1 and Phase 2 studies, ideally in inflammatory, immunologic, dermatologic, gastrointestinal, or metabolic disease

Working knowledge of ICH E6(R3), E2A and E2F, US IND safety reporting, MedDRA coding review, and SAE reconciliation, and of the early-phase safety assessments an oral small molecule needs (liver safety, QT, stopping rules)

Experience overseeing CRO or consultant medical monitors and pharmacovigilance vendors, and with blinded safety review committees and independent data monitoring committees

Data-driven judgment: you turn adverse event, laboratory, vital sign, and ECG data into clear decisions, protect the blind, and know when a participant's safety comes first

AI-native or AI-curious: you can say what a tool should do for a medical monitor, how you would check its output, and what it must never decide

Ego-lite, hands-on, and patient-first: collaborative, direct, no task too big or small, and never losing sight of who the trial is for

We hire for trajectory, not just credentials. If you meet most of the above and care deeply about this problem, we want to hear from you. 

ABOUT ENVEDA

We're a clinical-stage, AI-enabled biotech discovering medicines from nature four times faster than the industry standard. We recently raised $311M in a Series E, bringing total funding to over $845M, and doubled our valuation to $2B. We now have three oral medicines in the clinic, including our lead drug, ENV-294, in Phase 2 trials for eczema and asthma. Forbes named us one of America's Best Startup Employers, and Newsweek recognized us as a Top 100 Most Loved Workplace. We're still early, and most of the best work is ahead of us.

Benefits (Starting Day 1): Medical, dental, and vision covered at 90%, 401(k) with company match, flexible PTO and a company-wide weeklong recharge break, adoption assistance

Our Process: We move fast and respect your time. Typically: a recruiter screen → hiring manager conversation → work sample, technical interview, & culture interview.

Our Values: Curiosity | Agency | Journey | Charity | Unity

---------------------

Enveda is protecting Job Seekers

We care deeply about creating a safe, respectful experience for every applicant, so we wanted to share a few guidelines to help you spot anything that doesn’t feel right.

• You’ll always meet real Enveda team members through video or in-person conversations before receiving an offer.
• All communication from us will come from an @enveda.com or @envedabio.com email address.
• We’ll never ask you to purchase equipment, send money, or share sensitive banking details as part of any step in our recruiting process.

If something feels off or you’re unsure whether a message is truly from Enveda, please reach out at anytime at recruiting@enveda.com.

At Enveda, we’re building a place where everyone can do the best work of their life. We are an equal opportunity employer and value diversity in all its forms. Apply now and join a team committed to shaping the future of drug discovery.